Literature DB >> 16153209

Assessing the size and stage of testicular germ cell tumours: 1984-2003.

Jeetesh M Bhardwa1, Tom Powles, Dan Berney, Suhail Baithun, Vinod H Nargund, R Tim D Oliver.   

Abstract

OBJECTIVE: To assess the size and stage of testicular tumours on presentation in the period 1984-2002. PATIENTS AND METHODS: Demographic details and information on staging on 550 patients treated at St. Bartholomew's and the Royal London Hospital in the period 1984-2002 were collected prospectively in the departmental database. Information on testicular size was obtained by reviewing the histopathology records, and the maximum dimension of the tumour as measured in the gross specimen was taken as the size of the testicular tumour.
RESULTS: The period 1984-2002 was divided into three intervals, i.e. 1984-95, 1996-98 and 1999-2002. The mean testicular tumour size in the three intervals decreased from 4 cm (162 tumours) to 3.2 cm (85) and 2.5 cm (72; P = 0.002, Student's t-test). The proportion of tumours of <2 cm on presentation also increased, from 11% to 14% and 23% in the three intervals, respectively, while the proportion of patients with stage 1 disease increased from 57%, to 63% and 77%, respectively.
CONCLUSIONS: The size of testicular tumours on presentation has shown a consistent decline in the last two decades, the mean size now being 2.5 cm. That 23% are now <2 cm raises the possibility of testis-preserving surgery in this young group of patients, who have an excellent prognosis, and therefore in the long-term issues such as psychological morbidity and natural fertility assume greater importance. There is a need for a randomized controlled trial to evaluate these issues.

Entities:  

Mesh:

Year:  2005        PMID: 16153209     DOI: 10.1111/j.1464-410X.2005.05748.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.

Authors:  Mahmut Gumus; Ahmet Bilici; Hatice Odabas; Bala Basak Oven Ustaalioglu; Nurten Kandemir; Umut Demirci; Sener Cihan; Ibrahim Vedat Bayoglu; Turkan Ozturk; Esma Turkmen; Zurat Urakci; Mehmet Metin Seker; Yusuf Gunaydin; Fatih Selcukbiricik; Nedim Turan; Alper Sevinc
Journal:  World J Urol       Date:  2016-11-03       Impact factor: 4.226

2.  Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.

Authors:  Xiangdong Li; Shengjie Guo; Zhiming Wu; Pei Dong; Yonghong Li; Zhiling Zhang; Kai Yao; Hui Han; Zike Qin; Fangjian Zhou; Zhuowei Liu
Journal:  World J Urol       Date:  2014-12-04       Impact factor: 4.226

Review 3.  [Testis cancer: the UK as a model].

Authors:  S B Maddineni; N W Clarke
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

4.  Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation.

Authors:  Klaus-Peter Dieckmann; Hanna Richter-Simonsen; Magdalena Kulejewski; Raphael Ikogho; Henrik Zecha; Petra Anheuser; Uwe Pichlmeier; Hendrik Isbarn
Journal:  Urol Int       Date:  2018-04-12       Impact factor: 2.089

Review 5.  Testicular cancer.

Authors:  Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga
Journal:  Nat Rev Dis Primers       Date:  2018-10-05       Impact factor: 52.329

6.  Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.

Authors:  Axel Heidenreich; David Pfister
Journal:  Ther Adv Urol       Date:  2012-08

Review 7.  Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer.

Authors:  Madhur Nayan; Robert J Hamilton
Journal:  Adv Urol       Date:  2018-02-19

8.  Survival from testicular cancer in England and Wales up to 2001.

Authors:  R A Huddart
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.